1. Home
  2. COEP vs UTSI Comparison

COEP vs UTSI Comparison

Compare COEP & UTSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COEP
  • UTSI
  • Stock Information
  • Founded
  • COEP 2017
  • UTSI 1991
  • Country
  • COEP United States
  • UTSI China
  • Employees
  • COEP N/A
  • UTSI N/A
  • Industry
  • COEP Biotechnology: Biological Products (No Diagnostic Substances)
  • UTSI Telecommunications Equipment
  • Sector
  • COEP Health Care
  • UTSI Telecommunications
  • Exchange
  • COEP Nasdaq
  • UTSI Nasdaq
  • Market Cap
  • COEP 27.4M
  • UTSI 24.9M
  • IPO Year
  • COEP N/A
  • UTSI 2000
  • Fundamental
  • Price
  • COEP $10.72
  • UTSI $2.46
  • Analyst Decision
  • COEP
  • UTSI
  • Analyst Count
  • COEP 0
  • UTSI 0
  • Target Price
  • COEP N/A
  • UTSI N/A
  • AVG Volume (30 Days)
  • COEP 59.5K
  • UTSI 5.2K
  • Earning Date
  • COEP 08-15-2025
  • UTSI 09-04-2025
  • Dividend Yield
  • COEP N/A
  • UTSI N/A
  • EPS Growth
  • COEP N/A
  • UTSI N/A
  • EPS
  • COEP N/A
  • UTSI N/A
  • Revenue
  • COEP $62,874.00
  • UTSI $10,878,000.00
  • Revenue This Year
  • COEP N/A
  • UTSI N/A
  • Revenue Next Year
  • COEP N/A
  • UTSI N/A
  • P/E Ratio
  • COEP N/A
  • UTSI N/A
  • Revenue Growth
  • COEP N/A
  • UTSI N/A
  • 52 Week Low
  • COEP $2.31
  • UTSI $1.84
  • 52 Week High
  • COEP $13.70
  • UTSI $3.22
  • Technical
  • Relative Strength Index (RSI)
  • COEP 55.11
  • UTSI 44.91
  • Support Level
  • COEP $11.30
  • UTSI $2.39
  • Resistance Level
  • COEP $11.46
  • UTSI $2.63
  • Average True Range (ATR)
  • COEP 0.95
  • UTSI 0.07
  • MACD
  • COEP -0.05
  • UTSI -0.01
  • Stochastic Oscillator
  • COEP 38.82
  • UTSI 21.21

About COEP Coeptis Therapeutics Holdings Inc.

Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.

About UTSI UTStarcom Holdings Corp.

UTStarcom Holdings Corp is providing telecommunication network products, solutions and services. It focus on delivering carrier-class packet optical, network synchronization and broadband access (both wireless and fixed line) products and solutions, coupled with Software Defined Networking (SDN) platform, optimized for mobile backhaul, metro aggregation, broadband access and value added services. The business activity of the firm is operated through the Equipment and Service segment. The Equipment segment is focused on equipment sales, including network infrastructure and application products, and the Service segment is engaged in providing services and support of equipment products and also the new operational support. Key revenue is generated from Equipment segment.

Share on Social Networks: